Crossmark

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema

Published Online: 2021-10-09

Published Print: 2021-12

Authors

Gower, Richard G. http://orcid.org/0000-0002-5042-7059
Wilber, Mary
Funding

Funding for this research was provided by:

BioCryst Pharmaceuticals, Inc.
License Information

Text and Data Mining valid from 2021-10-09

Version of Record valid from 2021-10-09
More Information

Article History

Received: 13 April 2021

Accepted: 16 September 2021

First Online: 9 October 2021

Declarations

:

: Institutional approval was not sought as patient data were anonymized and all patients provided written consent for their information to be published.

: All patients provided written informed consent for publication.

: RGG is a clinical research investigator for BioCryst, Takeda, KalVista, CSL Behring, and Pharming; has accepted speaker fees for BioCryst, Pharming, Takeda, and CSL Behring; and has accepted advisory board and consulting fees from BioCryst, Takeda, CSL Behring, and Pharming. MW is a clinical research coordinator for BioCryst, KalVista, and Takeda; and has accepted advisory board and consulting fees from BioCryst.

Document is current